MHRA’s variations guidance says a reduced Type II procedure, shortened from 60 days to 30 days, is available for some safety-related variations when agreed between the agency and the marketing authorisation holder. The guidance says these are generally SmPC changes requested after PSUR assessment or at the request of the MHRA Pharmacovigilance Unit.
That matters because it shows some safety updates are treated as time-sensitive regulatory actions, not routine lifecycle administration. For companies, the challenge is not just identifying the issue but coordinating safety, regulatory, labeling, and operational functions quickly enough to meet the accelerated route. That coordination point is an inference, but it follows directly from the reduced timetable.
For compliance teams, this is a useful reminder that pharmacovigilance findings can trigger downstream regulatory work that must move with urgency and precision.
0 Comments